Jake Williams

Senior Director Business Development at IGM Biosciences, Inc. - Mountain View, California, US

Jake Williams's Colleagues at IGM Biosciences, Inc.
Shidong Ma

Sr. Scientist, Project leader

Contact Shidong Ma

Misbah Tahir

Chief Financial Officer

Contact Misbah Tahir

Lisa Decker

Chief Business Officer

Contact Lisa Decker

Bruce Keyt

Chief Scientific Officer

Contact Bruce Keyt

Marvin Peterson

Vice President, Process Sciences and Manufacturing

Contact Marvin Peterson

View All Jake Williams's Colleagues
Jake Williams's Contact Details
HQ
(650) 965-7873
Location
New York, New York, United States
Company
IGM Biosciences, Inc.
Jake Williams's Company Details
IGM Biosciences, Inc. logo, IGM Biosciences, Inc. contact details

IGM Biosciences, Inc.

Mountain View, California, US • 258 Employees
BioTech/Drugs

About IGM Biosciences, Inc. IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit www.igmbio.com. Imvotamab in Autoimmune and Inflammatory Diseases Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).

Lymphoma Treatment Hematologic Malignancies Autoimmune Disease
Details about IGM Biosciences, Inc.
Frequently Asked Questions about Jake Williams
Jake Williams currently works for IGM Biosciences, Inc..
Jake Williams's role at IGM Biosciences, Inc. is Senior Director Business Development.
Jake Williams's email address is ***@igmbio.com. To view Jake Williams's full email address, please signup to ConnectPlex.
Jake Williams works in the BioTech/Drugs industry.
Jake Williams's colleagues at IGM Biosciences, Inc. are Shidong Ma, Fred Schwarzer, Misbah Tahir, Lisa Decker, Bruce Keyt, Marvin Peterson, Suzette Tauber and others.
Jake Williams's phone number is (650) 965-7873
See more information about Jake Williams